The clinical interface of tuberous sclerosis complex and autism spectrum disorder: insights and future directions
Neurological Sciences · 2025-06 · 46 (6) · 2571-2580
DOI: 10.1007/s10072-025-08065-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurological Sciences, online erschienen am 25.02.2025. Verfasst von Reet Ramani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ziauddin Medical College, Ziauddin University, 4/B Shahrah-e-Ghalib Rd, Block 6 Clifton, Karachi, Karachi City, 75000, Sindh, Pakistan. Hauptthemen laut MEDLINE: Tuberous Sclerosis, Autism Spectrum Disorder. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Tuberous sclerosis complex (TSC) is a hereditary disorder that leads to tumor growth in various organs. Manifestations from mutations in the TSC1 or TSC2 genes comprise seizures, developmental delay, and skin abnormalities. This literature search has been dedicated to emphasizing the critical role of early diagnosis and the formulation of individualized plans for this target population with co-occurring TSC and Autism Spectrum Disorder (ASD). EXPERIMENTAL PROCEDURE: Behavioral and developmental tests can evaluate ASD symptoms; neuroimaging methods like functional MRI and PET scans can identify brain abnormalities, and molecular genetic analysis can detect TSC1/TSC2 mutations. Differential Diagnostic Approach These include medical histories and physical examinations to consider that ASD and TSC present the same symptoms. RESULTS: Although 90% of TSC patients are reported to have TSC-associated neuropsychiatric disorders, 30-50% of patients fulfil the clinical criteria of ASD. In comparison, the estimate for the rate of ASD prevalence in TSC patients ranges from 17 to 63%, with the characteristics of infantile spasms and early-onset epilepsy. The diagnosis is further challenged by the fact that there are shared symptoms between both, namely seizures and intellectual impairment. CONCLUSION: The shared symptoms between TSC and ASD suggest the need for multidisciplinary approaches in both diagnosis and treatment. A personalized therapeutic plan should include behavioral therapy, medication with Everolimus, mammalian target of rapamycin (mTOR) inhibitors, and advanced neuroimaging. The future of research in biomarkers, molecular medicines, and improving diagnostic protocols holds great promise for optimizing patient care and treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ziauddin Medical College, Ziauddin University, 4/B Shahrah-e-Ghalib Rd, Block 6 Clifton, Karachi, Karachi City, 75000, Sindh, Pakistan.
- Ziauddin Medical College, Ziauddin University, 4/B Shahrah-e-Ghalib Rd, Block 6 Clifton, Karachi, Karachi City, 75000, Sindh, Pakistan. hufsarana@outlook.com.
Zitieren
APA
Ramani, R., Fatima, B., Hussain, A., Shahid, U., Kamani, A., Bakar, S. M. A., Naveed, H., Naveed, T., Aftab, S. A., & Abbasi, A. Z. (2025). The clinical interface of tuberous sclerosis complex and autism spectrum disorder: insights and future directions. Neurological Sciences, 46(6), 2571-2580. https://doi.org/10.1007/s10072-025-08065-2
Vancouver
Ramani R, Fatima B, Hussain A, Shahid U, Kamani A, Bakar SMA, et al. The clinical interface of tuberous sclerosis complex and autism spectrum disorder: insights and future directions. Neurological Sciences. 2025;46(6):2571-2580. doi:10.1007/s10072-025-08065-2
BibTeX
@article{Ramani2025,
author = {Ramani, Reet and Fatima, Barika and Hussain, Abuzar and Shahid, Umer and Kamani, Aman and Bakar, Sahibzada Mohammad Abu and Naveed, Hufsa and Naveed, Tooba and Aftab, Saba Ambreen and Abbasi, Ahmed Zubair},
title = {The clinical interface of tuberous sclerosis complex and autism spectrum disorder: insights and future directions},
journal = {Neurological Sciences},
year = {2025},
volume = {46},
number = {6},
pages = {2571--2580},
doi = {10.1007/s10072-025-08065-2}
}
EUVIMED